Exercise for Patients With Renal Cell Cancer Receiving Sunitinib

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT00869011
• Date of registration: 23/03/2009
• Primary sponsor: Charite University, Berlin, Germany
• Public title: Exercise for Patients With Renal Cell Cancer Receiving Sunitinib
• Scientific title: Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib)
• Date of first enrolment: December 2009
• Target sample size: 70
• Recruitment status: Recruiting
• URL: http://clinicaltrials.gov/show/NCT00869011
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care

Countries of recruitment

Germany

Contacts

• Name: Fernando C. Dimeo, MD

• Name: Fernando C. Dimeo, MD

Key inclusion & exclusion criteria

Inclusion Criteria:

- 18 to 75 years

- Understanding of written German

- Treatment with Sunitinib

- Ability to walk

Exclusion Criteria:

- Cardiovascular, pulmonary or osteoarticular disease which can be aggravated by
exercise

- BMI < 18 or > 30



Age minimum: 18 Years
Age maximum: 75 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Renal Cell Carcinoma

Intervention(s)

Other: Endurance exercise

Primary Outcome(s)

Fatigue [Time Frame: 12 weeks]

Secondary Outcome(s)

Depression score [Time Frame: 12 weeks]

Systolic and diastolic blood pressure (24 h) [Time Frame: 12 weeks]

VO2max [Time Frame: 12 weeks]

Secondary ID(s)

SUIR8687

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Pfizer